Fresenius plans to invest more than EUR 200 million in venture fund over next 5 years

Fresenius plans to invest more than EUR 200 million in a venture fund over the next 5 years.

• Fresenius launched Fresenius Ventures, a corporate venture capital unit, to invest in healthcare innovators from early rounds through growth stage.
• Planned investment volume exceeds EUR 200 million over the next 5 years, targeting areas adjacent to its BioPharma, MedTech, care provision platforms.
• The strategy aims to secure earlier access to new technologies, business models, founders, backed by clinical, regulatory, operational support.
• Dr. Thomas Michael Thestrup will lead the unit, bringing corporate venture capital experience from Angelini Ventures.